Take­da swoops in to buy lit­tle biotech part­ner and its celi­ac drug poised to 'change stan­dard of care'

Hav­ing spent three years care­ful­ly groom­ing PvP Bi­o­log­ics and its drug for celi­ac dis­ease, Take­da is hap­py enough with the proof-of-con­cept da­ta to buy it all.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER